Head to Head Comparison: Nutriband (NASDAQ:NTRB) and ProPhase Labs (NASDAQ:PRPH)

ProPhase Labs (NASDAQ:PRPH) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares ProPhase Labs and Nutriband”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.05 million	0.05	-$53.36 million	($2.25)	-0.01
Nutriband	$2.04 million	41.31	-$8.23 million	($0.53)	-13.08

Nutriband has lower revenue, but higher earnings than ProPhase Labs. Nutriband is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ProPhase Labs and Nutriband, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
Nutriband	1	1	0	0	1.50

Institutional and Insider Ownership

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 52.2% of Nutriband shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

ProPhase Labs has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares ProPhase Labs and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Nutriband	-430.35%	-109.07%	-95.54%

Summary

Nutriband beats ProPhase Labs on 9 of the 12 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.